KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $4.0 billion.

  • Pfizer's Free Cash Flow fell 74.42% to $4.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 billion, marking a year-over-year decrease of 2619.85%. This contributed to the annual value of $9.8 billion for FY2024, which is 10519.51% up from last year.
  • Latest data reveals that Pfizer reported Free Cash Flow of $4.0 billion as of Q3 2025, which was down 74.42% from -$1.2 billion recorded in Q2 2025.
  • Pfizer's 5-year Free Cash Flow high stood at $25.3 billion for Q4 2021, and its period low was -$2.4 billion during Q2 2024.
  • Over the past 5 years, Pfizer's median Free Cash Flow value was $4.0 billion (recorded in 2021), while the average stood at $5.2 billion.
  • In the last 5 years, Pfizer's Free Cash Flow crashed by 12857.91% in 2023 and then surged by 42876.71% in 2024.
  • Over the past 5 years, Pfizer's Free Cash Flow (Quarter) stood at $25.3 billion in 2021, then dropped by 27.03% to $18.5 billion in 2022, then plummeted by 77.26% to $4.2 billion in 2023, then dropped by 3.93% to $4.0 billion in 2024, then fell by 0.74% to $4.0 billion in 2025.
  • Its last three reported values are $4.0 billion in Q3 2025, -$1.2 billion for Q2 2025, and $1.8 billion during Q1 2025.